<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03773003</url>
  </required_header>
  <id_info>
    <org_study_id>IMPROFA</org_study_id>
    <nct_id>NCT03773003</nct_id>
  </id_info>
  <brief_title>Research for Pathophysiology of Cancer Related Fatigue (CRF) and Chronic Fatigue (CFS/ME)</brief_title>
  <acronym>IMPROFA</acronym>
  <official_title>Pathophysiology of Cancer Related Fatigue (CRF) and Chronic Fatigue (CFS/ME) by Lipidomics, Metabolomics, Microbiome and Exome Analysis and Investigation of Clinical Improvement Under Administration of Probiotics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Saarland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Saarland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research for Pathophysiology of Cancer Related Fatigue (CRF) and Chronic Fatigue Syndrome
      (CFS/ME) by Lipidomics, Metabolomics, Intestinal and Peritoneal Microbiome Analysis and Exome
      Analysis and Investigation of a Possible Benefit of Probiotics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to identify the underlying pathophysiology of Cancer Related Fatigue (CRF) by
      screening lipidome, metabolome, exome and microbiome of affected patients with tumor disease
      with and without fatigue. These results will be compared to an age- and gender matched
      control group with a comparable tumor disease and to another age- and gender matched control
      group without tumor disease.

      The investigators are following the same strategy for investigating an underlying
      pathophysiology of Chronic Fatigue Syndrome (CFS/ME) in another group of patients. The age-
      and gender matched control group will be established from the beforementioned control group.

      The investigators will also be screening for a peritoneal microbiome (possible correlate for
      leaky gut) in study patients undergoing abdominal surgery.

      We will also investigate changes in fatigue and in lipidome, metabolome, exome and microbiome
      by double-blinded, placebo-controlled administration of probiotics to the study population.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blinded, placebo controlled intervention with probiotics
There are three groups in the study:
Tumor disease with fatigue
Tumor disease without fatigue
Healthy control group</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>Blinding will be made at the probiotics manufacturer's establishment. Neither investigators nor care providers nor patients know their status til the end of the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of fatigue symptoms</measure>
    <time_frame>3 months after end of chemotherapy</time_frame>
    <description>Improvement of fatigue as measured by validated psychometric questionnaires.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Cancer Related Fatigue</condition>
  <condition>Fatigue Syndrome, Chronic</condition>
  <arm_group>
    <arm_group_label>Arm 1: Tumor disease w/o fatigue</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group receiving probiotics.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Tumor disease w/o fatigue</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group receiving placebo (corn starch)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: Healthy control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group receiving probiotics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: Healthy control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group receiving placebo (corn starch)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotics</intervention_name>
    <description>The administered probiotics are readily available on the market and contain
Bifidobacterium breve, B. infantis, B. lactis, B. longum
Lactobacillus acidophilus, L. bulgaricus, L. casei, L. crispatus, L. fermentum, L. paracasei, L. plantarum, L. reuteri, L. rhamnosus, L. salivarius
Streptococcus thermophilus</description>
    <arm_group_label>Arm 1: Tumor disease w/o fatigue</arm_group_label>
    <arm_group_label>Arm 3: Healthy control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identically looking to verum, containing corn starch.</description>
    <arm_group_label>Arm 2: Tumor disease w/o fatigue</arm_group_label>
    <arm_group_label>Arm 4: Healthy control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically, cytologically or radiologically confirmed tumor disease

          -  indication for chemotherapy

          -  Written consent to participation

        Exclusion Criteria:

          -  chronic-inflammatory bowel disease

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Jelden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Saarland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Jelden, MD</last_name>
    <phone>+4968411630000</phone>
    <email>michael.jelden@uks.eu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Saarland University Medical Center</name>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66424</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Jelden, Dr.</last_name>
      <phone>+49684116</phone>
      <phone_ext>30000</phone_ext>
      <email>michael.jelden@uks.eu</email>
    </contact>
    <contact_backup>
      <last_name>Michael Jelden, Dr.</last_name>
      <phone>49684116</phone>
      <phone_ext>15000</phone_ext>
      <email>michael.jelden@uks.eu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Jelden, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>December 10, 2018</study_first_submitted>
  <study_first_submitted_qc>December 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2018</study_first_posted>
  <last_update_submitted>August 21, 2019</last_update_submitted>
  <last_update_submitted_qc>August 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Saarland</investigator_affiliation>
    <investigator_full_name>Michael Jelden, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Cancer Fatigue, Chronic Fatigue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue Syndrome, Chronic</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

